13,14-dihydroprostaglandin e1 has been researched along with 5-hydroxydecanoate in 1 studies
| Studies (13,14-dihydroprostaglandin e1) | Trials (13,14-dihydroprostaglandin e1) | Recent Studies (post-2010) (13,14-dihydroprostaglandin e1) | Studies (5-hydroxydecanoate) | Trials (5-hydroxydecanoate) | Recent Studies (post-2010) (5-hydroxydecanoate) |
|---|---|---|---|---|---|
| 27 | 2 | 3 | 431 | 0 | 93 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hide, EJ; Ney, P; Piper, J; Thiemermann, C; Vane, JR | 1 |
1 other study(ies) available for 13,14-dihydroprostaglandin e1 and 5-hydroxydecanoate
| Article | Year |
|---|---|
Reduction by prostaglandin E1 or prostaglandin E0 of myocardial infarct size in the rabbit by activation of ATP-sensitive potassium channels.
Topics: Adenosine Triphosphate; Alprostadil; Animals; Anti-Arrhythmia Agents; Biotransformation; Blood Pressure; Decanoic Acids; Electrocardiography; Glyburide; Heart Rate; Hydroxy Acids; Hypoglycemic Agents; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Potassium Channels; Rabbits; Vasodilator Agents | 1995 |